One year of ND0612 reduced off time, increased good on time

A year of treatment with ND0612, an investigational continuous subcutaneous infusion of levodopa/carbidopa, significantly reduced off periods when motor symptoms were poorly controlled and improved quality of life in people with advanced Parkinson’s disease. According to data from the BouNDless study and its open-label extension, BeyoND, presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders, ND0612 provided steady symptom control compared to immediate-release oral levodopa/carbidopa. Patients using ND0612 showed improvements in motor symptoms like speech, tremor, and self-care, and enhanced quality of life across multiple domains, including mobility, communication, and emotional well-being. ND0612 was generally well tolerated, with the most common side effects being infusion site reactions and issues similar to those seen with oral therapy, such as dyskinesia and falls. Long-term data from the BeyoND extension study showed a sustained reduction of 2 hours in off time and an increase in on time without troublesome dyskinesia over six months and one year. The U.S. FDA is currently reviewing ND0612 for potential approval, offering hope for a new treatment option for people with Parkinson’s experiencing motor fluctuations.